York Gwill 4
4 · Alto Neuroscience, Inc. · Filed Feb 7, 2024
Insider Transaction Report
Form 4
York Gwill
Director
Transactions
- Conversion
Common Stock
2024-02-06+23,917→ 23,917 total - Conversion
Series A Preferred Stock
2024-02-06−53,196→ 0 total→ Common Stock (23,917 underlying)
Footnotes (1)
- [F1]Each share of Series A Preferred Stock was convertible at any time, at the holder's election, and automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.2241 for 1 basis and had no expiration date.